Log In
BCIQ
Print this Print this
 

hGH-CTP, Lagova (MOD-4023, PF-06836922)

  Manage Alerts
Collapse Summary General Information
Company Opko Health Inc.
DescriptionLong-acting human growth hormone (hGH) combined with the company's carboxyl terminal peptide (CTP) technology
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase III
Standard IndicationGrowth hormone deficiency
Indication DetailsTreat growth hormone deficiency (GHD)
Regulatory Designation U.S. - Orphan Drug (Treat growth hormone deficiency (GHD));
EU - Orphan Drug (Treat growth hormone deficiency (GHD))
PartnerPfizer Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$570.0M

$295.0M

$275.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/15/2014

$570.0M

$295.0M

$275.0M

Get a free BioCentury trial today